Glenn became Chief Scientific Officer in 2024, previously serving as Senior Vice President of Early Development since joining atai in 2019. He leads internal innovation, overseeing early-stage product development and integrating translational medicine into development and clinical strategies.

Short has 15 years of industry and research experience and has been involved in numerous programs that leverage cutting-edge biotechnologies to develop new therapies to address unmet medical needs. He has held multiple senior leadership positions across the industry. Early in his research career, he discovered and patented a novel drug class of Nav1.7 ion channel antagonists that selectivity inhibited a confirmation of the ion channel involved in promoting pain signalling.

He received his Ph.D. in Bioorganic Chemistry and conducted his postdoctoral training in Molecular Biology at Massachusetts General Hospital/Harvard Medical School in Boston. He also holds a B.A. in Chemistry from the University of Virginia.